Introduction
Optimal neurological recovery after successful cardiopulmonary resuscitation (CPR) is the most important aspect of post-resuscitation care because it directly affects the final outcome. Proper oxygenation, blood pressure control, normoglycemia and therapeutic hypothermia are established measures in immediate post-resuscitation care, which promote variable degrees of cerebral recovery. A brief period of cerebral hyperemia after return of spontaneous circulation 11 -14 (ROSC) (1) is followed by decreased brain perfusion. Unstable, post-resuscitation hemodynamics, together with the initial hypoxic-ischemic injury, lead to further neurological damage. Despite the increased incidence of ROSC and overall survival, poor functional recovery of successfully resuscitated cardiac arrest victims demands further research in the field of post-resuscitation care. Exogenous erythropoietin (EPO) has been shown to promote neuroprotection in hypoxic-ischemic cerebral insult by regulating neurogenesis, and preventing neuronal apoptosis (2-4). These protective properties of EPO, in ischemic brain damage, could benefit patients who have survived a cardiac arrest.
Neuroprotective role of erythropoietin in cerebral ischemia
As nature proves, the simplest and yet the most important solutions lie in the capability of nature to renew itself from its own resources. EPO, a vital compound of erythroid differentiation, is also involved in non-hematopoietic tissue protective pathways with its antiapoptotic, anti-inflammatory, angiogenetic, and neurotrophic properties (5). The evidence shows that hypoxia increases production of EPO not only in kidneys, but also in brain, testis, liver, and spleen (6-8). In brain, EPO is highly expressed after neuropathological insult (6). Astrocytes produce EPO after its upregulation due to hypoxia, and neurons express EPO receptors (3,8). It has also been shown that after systemic administration, EPO promotes neuroprotection even in severe cerebral ischemia (9), enhances neurological recovery in traumatic brain and spinal cord injury (6,10-13), and prevents the loss of autoregulation of cerebral blood flow (14) . This evidence of neuroprotection and restructuring of cerebral tissue after neuropathological insult could be the rationale for using EPO in clinical practice to limit neuronal damage (15) . Even though the blood-brain barrier prevents transport of systemic EPO into brain, hypoxic-ischemic brain conditions disrupt the blood-brain barrier, making brain cells accessible to intravenously administered EPO (16) . There is an increasing body of evidence suggesting that EPO crosses the bloodbrain barrier in human and animal models, after peripheral application (4,6,14,17-21). Usefulness of EPO as a therapeutic agent in hypoxic-ischemic cerebral conditions is thus based on its capability to cross the blood-brain barrier, upregulation of its expression in hypoxic conditions, neuroprotective and neurogenetic potential, and good clinical tolerance (14, 20, 22) .
Erythropoietin in cardiopulmonary resuscitation: are we near?
Cerebral ischemia is inevitable during cardiac arrest and at some extent during the post-resuscitation period. During the first few hours of recovery from cardiac arrest, the brain remains hypoxic, but for no more than 2 days (23) . After a hypoxic-ischemic insult, hypoxia inducible factor (HIF) isoforms, HIF-1 alpha and HIF-2 alpha, stimulate the expression of EPO in brain astrocytes (23) (24) (25) . In the brain, HIF-1 alpha accumulates early during recovery from cardiac arrest, and persists for several days after successful resuscitation (23) . Intrinsic EPO, produced by the majority of brain cells after HIF stimulation (26) , and exogenous EPO, protect neuronal tissue from oxygen deprivation and other noxious stimuli, promote neuroangiogenesis, inhibit hypoxia-induced apoptosis in neurons, and thus support the survival of neurons in the ischemic brain (4, 16, [25] [26] [27] [28] [29] . In the proximity of infarcted areas of the brain there is a degree of angiogenesis, axonal reorganization with neurogenesis, and neuroblast migration to areas exposed to ischemic injury, which is in part mediated by EPO (30, 31) . In an adult animal model of ischemic stroke, exogenous EPO reduces an infarct size (2,4,17,26,32). In the neonatal animal model, exogenous EPO improves asymmetry of forelimbs following stroke (18) , reduces the infarct size with attenuation of brain injury, and preserves the integrity of cerebral cortex (33, 34) . EPO induces time-and dose-dependent tolerance against oxygen and glucose deprivation in primary cortical neurons and protects from cell death. The protection is significant within minutes and lasts up to 48 hours after continued EPO exposure (27) . In vivo, the protective properties are most prominent when EPO is given early after focal or global cerebral hypoxic-ischemic insult, which in turn improves longterm neurobehavioral achievements (17, 32, 33, 35, 36) . The therapeutic time window for tissue protection by EPO is very wide in experimental models (37) . This evidence makes EPO a potent therapeutic agent for neurological emergencies with the purpose to improve functional recovery (25, 26, 30) , and could also present a rationale for treatment with EPO after successful CPR.
What does the future hold?
A pioneer work by Ehrenreich et al. (19) , regarding the impact of EPO on hypoxicischemic cerebral damage in humans, showed that intravenous high-dose recombinant EPO, a total of 100.000 units given in the first three days after acute ischemic stroke, is well tolerated and improves clinical outcome. Evidence shows that doses of at least 500 units/kg of body weight of EPO given intravenously, offer significant tissue protection, and that tissue-protecting properties of EPO start at peak serum concentrations of 50 ng/ml for central nervous system lesions (38) . In the central nervous system, tissue protecting mechanisms require doses that are higher than those for stimulation of erythropoiesis (5), while in other tissues like heart, cytoprotection could be accomplished with lower doses (39) . Nevertheless, optimal recombinant EPO or its analogues, dose characteristics, and the therapeutic window for EPO use in humans have to be determined yet in order to provide appropriate tissue protection, and lower the incidence of adverse effects. The later mainly consist of increased hematocrit and platelet aggregability which significantly increases the risk of thrombosis (5), and high-risk patients are those with polycythemia-hyperviscosity syndrome, hypertension, and vascular thrombosis (40) . Non-erythropoietic tissue-protective derivates of EPO, like asialo EPO and carbamylated EPO, still provide neuroprotection, and avoid adverse effects at the same time (36, (40) (41) (42) . In summary, upregulation of EPO in hypoxic-ischemic human brain, ability of exogenous EPO to cross the bloodbrain barrier after peripheral application, its neuroprotective role in animal and human studies, pleiotrophism, and clinical tolerance give a strong rationale for further research of the impact of EPO on neurological recovery after successful cardiopulmonary resuscitation in humans.
